en · de · es · fr · pt
thymosin-alpha-1-notes.peptides6908.com › Topic › Molecular Structure And Biological Background — Worked Examples

Molecular Structure And Biological Background — Worked Examples

By Editorial Desk · published 2026-05-09 · last reviewed 2026-06-18 · Topic

immunomodulator raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-06-18. Anything still debated is marked as such rather than presented as settled.

Molecular Structure and Biological Background

Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.

Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.

Background and Mechanism of Action

Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.

Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.

Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Chemical classSynthetic peptide, 28 residuesN-terminal fragment of prothymosin alpha
Molecular massAbout 3108 DaAcetylated form
Isoelectric pointNear 4.2Acidic peptide
AppearanceWhite to off-white lyophilized powderCommon supplied form
Typical storage-20 °C or below, drySolution stability is lower

分子身份与天然来源

胸腺素α1(thymosin alpha 1,Tα1)是一种由28个氨基酸组成的酸性肽,N端被乙酰化,分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离,属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守,提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置,并非表示亚型编号。它既存在于胸腺,也存在于脾脏和淋巴结等免疫组织。

20世纪70年代,研究者从胸腺提取物中纯化出多种小肽,Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤,产量低且成分复杂。随着固相肽合成技术成熟,实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上,并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。

Related pages on this site

Research History and Clinical Assessment

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.

Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.

Background and Molecular Profile

The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.

Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.

The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.

Molecular Identity Of Thymosin Alpha-1

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Notes from published material

To revitalize the economy, from 1971 the Gierek regime introduced wide-ranging reforms that involved large-scale foreign borrowing. These actions initially caused improved conditions for consumers, but in a few years the strategy backfired and the economy deteriorated. Another attempt to raise food prices resulted in the June 1976 protests. The Workers' Defence Committee (KOR), established in response to the crackdown that followed, consisted of dissident intellectuals determined to support industrial workers, farmers and students persecuted by the authorities. The opposition circles active in the late 1970s were emboldened by the Helsinki Conference processes. In October 1978, the Archbishop of Kraków, Cardinal Karol Józef Wojtyła, became Pope John Paul II, head of the Catholic Church. Catholics and others rejoiced at the elevation of a Pole to the papacy and greeted his June 1979 visit to Poland with an outpouring of emotion. Fueled by large infusions of Western credit, Poland's economic growth rate was one of the world's highest during the first half of the 1970s, but much of the borrowed capital was misspent, and the centrally planned economy was unable to use the new resources effectively. The 1973 oil crisis caused recession and high interest rates in the West, to which the Polish government had to respond with sharp domestic consumer price increases. The growing debt burden became insupportable in the late 1970s, and negative economic growth set in by 1979.

Chain-ganging occurs when a state sees its own security tied to the security of its alliance partner. It chains itself by deeming any attack on its ally the equivalent of an attack on itself. That is another aspect of the balance of power theory, whereby the smaller states could drag their chained states into wars that they have no desire to fight. A key example was the chain-ganging between states prior to World War I, dragging most of Europe to war over a dispute between the relatively major power of Austria-Hungary and the minor power of Serbia. Thus, states "may chain themselves unconditionally to reckless allies whose survival is seen to be indispensable to the maintenance of the balance".

=== Analogues and derivatives === Analogues of 2C-B include 2C-I, 2C-C, DOB, 4C-B, 2C-B-FLY, and 25B-NBOMe, among others. DOB and 4C-B are α-alkyl derivatives of 2C-B, specifically the amphetamine (α-methyl) and phenylisobutylamine (α-ethyl) derivatives, respectively. β-Substituted derivatives of 2C-B such as BOB (β-methoxy-2C-B), BOH-2C-B (β-hydroxy-2C-B), βk-2C-B (β-keto-2C-B), and β-methyl-2C-B (BMB) have been described. βk-2C-B shows dramatically reduced potency and efficacy as a serotonin 5-HT2A receptor agonist compared to 2C-B. A variety of N-substituted derivatives of 2C-B have been tested, including N-methyl-2C-B, N,N-dimethyl-2C-B, N-ethyl-2C-B, and N-benzyl-2C-B. Most simple alkyl derivatives were considerably less potent than 2C-B, with N-ethyl-2C-B for instance having a 40 times lower affinity for the serotonin 5-HT2A receptor. The N-benzyl derivative however was found to have higher affinity than 2C-B itself, with N-(4-bromobenzyl)-2C-B binding even more tightly. This initial research did not include functional assays of activity, but later led to the development of potent substituted N-benzyl derivatives such as 25B-NBOMe, and 25B-NBOH. Another N-substituted derivative, 2C-B-AN, is an N-benzylphenethylamine-like prodrug of 2C-B. 2C-DB (6-bromo-2C-B) is a ring-substituted derivative of 2C-B. TWEETIO derivatives of 2C-B, in which one or both of the methoxy groups of 2C-B are extended to ethoxy groups, exist as well, such as 2CB-2-EtO.

Sources: en.wikipedia.org

Further detail

Selenium has six natural isotopes that occur in significant quantities, along with the trace isotope 79Se, which occurs in minute quantities in uranium ores. Five of these isotopes are stable: 74Se, 76Se, 77Se, 78Se, and 80Se. The last three also occur as fission products, along with 79Se, which has a half-life about 330,000 years, and 82Se, which has the very long half-life of 8.76×1019 years as it decays via double beta decay to krypton-82 and for practical purposes can be considered to be stable. There are 23 other unstable isotopes that have been characterized, the longest-lived after 79Se being 75Se with its half-life 119.78 days, 72Se at 8.40 days, and 73Se at 7.15 hours. The others are all under an hour and most do not exceed 38 seconds.

The Fascism and Freedom Movement – National Socialist Party (Italian: Movimento Fascismo e Libertà – Partito Socialista Nazionale, MFL–PSN), or simply Fascism and Freedom Movement, is an Italian fascist political party formed on 25 July 1991 by Giorgio Pisanò.

From 1930, white women had the vote, and the right to serve as senators and MPs, on the same basis as white men. In 1934, Parliament was declared "the sovereign legislative power in and over the Union". From 1937, black voters were separated from the other races – in the Senate they were represented by four elected senators (two for the Cape, one for Natal, one for the Orange Free State and Transvaal), and in the House of Assembly by three "native representative" MPs elected in separate black constituencies. From 1950, white voters in South West Africa, which was under South African administration at that time, were represented by four senators and six MPs. From 1957, Coloured voters were separated from the whites – in the Senate, they were represented by separate senators, and in the House of Assembly by MPs elected in separate Coloured constituencies. To pass this amendment in the face of strong opposition (and two Supreme Court rulings), prime minister Johannes Strijdom had to enlarge the Senate and appoint enough pro-government senators to get the two-thirds majority he needed to force through the constitutional change. Representation of black voters was ended in 1960. Voting age was lowered from 21 to 18 in 1960. In a referendum held in 1960, a small majority of white voters approved the conversion of the country from a constitutional monarchy to a parliamentary republic.

Sources: en.wikipedia.org

Frequently asked questions

Is thymosin alpha-1 a naturally occurring hormone?

It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.

What is the difference between thymosin alpha-1 and other thymosins?

Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.

Does the peptide work by a single known mechanism?

No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.

Is thymosin alpha-1 a hormone?

It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.

Network